Am I a Candidate for a Hair Transplant? Evaluation Criteria

Determining candidacy for a hair transplant involves a structured clinical evaluation that weighs donor supply, hair loss pattern, overall health status, and realistic outcome expectations. The process is not a simple checklist — it requires physician assessment against established classification frameworks and surgical safety standards. Understanding the criteria used helps patients approach the consultation process with accurate expectations and relevant medical history prepared.

Definition and scope

Hair transplant candidacy refers to the medical determination of whether a patient's anatomy, physiology, and hair loss profile make them a suitable recipient for follicular transplantation surgery. The evaluation applies to both Follicular Unit Extraction (FUE) and Follicular Unit Transplantation (FUT), as each technique carries distinct donor-area requirements and scar profiles.

The scope of candidacy assessment extends beyond cosmetic preference. The U.S. Food and Drug Administration classifies hair transplant surgery as a medical procedure, and the tools used in robotic or laser-assisted systems are regulated as Class II or Class III devices under 21 CFR Part 878. The regulatory framework governing hair restoration establishes that patient selection is a physician-supervised clinical decision, not a marketing determination.

Candidacy evaluation addresses four core domains:

  1. Donor density and supply — whether the occipital and parietal scalp contains sufficient permanent follicular units
  2. Hair loss classification stage — position on standardized scales such as the Norwood scale for men or the Ludwig scale for women
  3. Medical eligibility — presence or absence of contraindicated conditions
  4. Stability of hair loss — whether active loss has reached a plateau or remains progressive

How it works

A formal candidacy evaluation typically follows a structured clinical sequence. The International Society of Hair Restoration Surgery (ISHRS), the leading professional body in this specialty, publishes practice standards that inform how physicians conduct these assessments.

Step 1 — Hair loss classification. The physician maps the patient's pattern against the Norwood Scale (men) or Ludwig Scale (women). Norwood Stages I–III generally represent the earliest intervention windows; Stages VI–VII present the most constrained donor-to-recipient ratios. A patient at Norwood Stage VII, for instance, may have insufficient donor supply to achieve meaningful density in a significantly expanded recipient zone.

Step 2 — Donor area assessment. Donor density is measured in follicular units per square centimeter. A density below approximately 40 follicular units/cm² in the permanent donor zone may limit the total grafts extractable without visible thinning of the donor site. The ISHRS notes that total safe donor capacity typically ranges between 4,000 and 8,000 grafts over a lifetime, though individual anatomy determines the actual ceiling.

Step 3 — Medical history review. Contraindications are screened, including active autoimmune alopecia (such as alopecia areata), uncontrolled systemic disease, bleeding disorders, or scalp conditions that compromise graft survival. Patients on anticoagulants require clearance from their prescribing physician before any surgical planning proceeds.

Step 4 — Scalp laxity and caliber assessment. FUT candidacy specifically requires adequate scalp laxity for strip excision. Hair shaft caliber — coarse versus fine — also affects the visual density achievable per graft unit. Coarser hair typically delivers higher perceived coverage per follicular unit transplanted.

Step 5 — Psychological and expectation screening. The American Board of Hair Restoration Surgery (ABHRS) and ISHRS both emphasize that unrealistic outcome expectations are a recognized contraindication. Patients expecting full restoration to pre-loss density are generally counseled that transplantation redistributes existing follicles rather than generates new ones.

Common scenarios

Male androgenetic alopecia (AGA): The most statistically frequent presentation. Patients at Norwood Stages III–V with stable loss, adequate donor density, and no active autoimmune component represent the core surgical candidate profile. Androgenetic alopecia accounts for the overwhelming majority of hair transplant procedures performed in the United States.

Female pattern hair loss: Women represent a distinct candidacy profile. The Ludwig Scale grades female diffuse thinning from I to III, but a critical differentiator is whether the patient's donor zone is itself affected by diffuse loss — which would disqualify transplantation. Women with stable donor areas and defined recession patterns (such as frontal hairline recession rather than global diffuse thinning) are more likely to meet candidacy thresholds.

Scarring from trauma or prior procedures: Patients with traction alopecia, burn scars, or scarring from prior surgeries may qualify with modified expectations. Scarring alopecia cases require biopsy confirmation that the scarring process is inactive before transplantation into affected zones.

Post-chemotherapy hair loss: Candidacy in this group depends on whether follicle loss is permanent or temporary. Hair restoration after chemotherapy is typically deferred until regrowth has stabilized — often 12 months post-treatment — to confirm permanent follicle loss before committing donor supply.

Decision boundaries

Clear disqualifying factors include active scalp infection, keloid scarring history (which increases risk of hypertrophic donor-site scarring), uncontrolled diabetes, and active alopecia areata. Age is a functional boundary rather than an absolute one — patients under 25 are generally considered high-risk candidates because hair loss trajectory remains unpredictable, making it difficult to design a hairline that ages appropriately as loss continues.

The contrast between good candidates and marginal candidates turns primarily on three variables: donor supply adequacy, loss stability, and realistic outcome framing. A patient with Norwood Stage IV loss, stable for 3 years, 60+ follicular units/cm² in the donor zone, and documented expectations calibrated to redistribution — not restoration — meets the core profile. A patient with rapid ongoing loss, a compromised donor area, and expectations of full youthful density does not.

Combining surgical candidacy review with an assessment of medical adjuncts — including finasteride or minoxidil for stabilizing ongoing loss — is standard practice. The hair restoration overview at the site index provides broader context on how surgical and non-surgical pathways are structured within the full treatment landscape.

Patients considering candidacy outside the United States should also review the specific risks documented in medical tourism for hair transplants, as regulatory oversight standards vary substantially across jurisdictions.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)